Biopharmaceutical company Enveric Biosciences announced today that Gilgamesh Pharmaceuticals has officially withdrawn its post-grant review request for a patent previously filed against Enveric Biosciences.
Show original
This development marks a significant achievement for Enveric Biosciences in safeguarding its intellectual property. Patents are core assets for biotechnology companies, and successfully defending them helps protect the value of the company's R&D investments and future market potential. With the withdrawal of the challenge, Enveric Biosciences can now focus more on advancing its pipeline of therapeutics for neuropsychiatric disorders.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Trending news
MoreAccording to the latest public documents from the U.S. Securities and Exchange Commission (SEC), Steakholder Foods has submitted an application, planning for selling shareholders to offer up to 5.7 million American Depositary Shares (ADS).
BlackRock Utilities, Infrastructure, & Power Opportunities Trust (BUI) has officially announced the specific terms of its equity offering.
Crypto prices
More
Bitcoin
BTC
$65,528.5
-2.99%
Ethereum
ETH
$1,918.84
-5.63%
Tether USDt
USDT
$0.9999
+0.00%
BNB
BNB
$611.26
-2.03%
XRP
XRP
$1.35
-3.42%
USDC
USDC
$0.9999
+0.00%
Solana
SOL
$81.31
-5.57%
TRON
TRX
$0.2829
-1.04%
Dogecoin
DOGE
$0.09307
-3.77%
Cardano
ADA
$0.2759
-3.62%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now